JP2024001135A5 - - Google Patents

Info

Publication number
JP2024001135A5
JP2024001135A5 JP2023172414A JP2023172414A JP2024001135A5 JP 2024001135 A5 JP2024001135 A5 JP 2024001135A5 JP 2023172414 A JP2023172414 A JP 2023172414A JP 2023172414 A JP2023172414 A JP 2023172414A JP 2024001135 A5 JP2024001135 A5 JP 2024001135A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
polypeptide
human
days
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023172414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024001135A (ja
Filing date
Publication date
Priority claimed from PCT/EP2019/052929 external-priority patent/WO2019154867A1/en
Application filed filed Critical
Publication of JP2024001135A publication Critical patent/JP2024001135A/ja
Publication of JP2024001135A5 publication Critical patent/JP2024001135A5/ja
Pending legal-status Critical Current

Links

JP2023172414A 2018-02-06 2023-10-04 Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法 Pending JP2024001135A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862627082P 2018-02-06 2018-02-06
US62/627,082 2018-02-06
US201862662381P 2018-04-25 2018-04-25
US62/662,381 2018-04-25
PCT/EP2019/052929 WO2019154867A1 (en) 2018-02-06 2019-02-06 Methods of treating initial episode of ttp with immunoglobulin single variable domains
JP2020563820A JP2021512947A (ja) 2018-02-06 2019-02-06 Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020563820A Division JP2021512947A (ja) 2018-02-06 2019-02-06 Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法

Publications (2)

Publication Number Publication Date
JP2024001135A JP2024001135A (ja) 2024-01-09
JP2024001135A5 true JP2024001135A5 (https=) 2025-11-17

Family

ID=65440943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563820A Pending JP2021512947A (ja) 2018-02-06 2019-02-06 Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
JP2023172414A Pending JP2024001135A (ja) 2018-02-06 2023-10-04 Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020563820A Pending JP2021512947A (ja) 2018-02-06 2019-02-06 Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法

Country Status (15)

Country Link
US (1) US11999797B2 (https=)
EP (1) EP3749696A1 (https=)
JP (2) JP2021512947A (https=)
KR (1) KR102929403B1 (https=)
CN (1) CN111670202A (https=)
AU (1) AU2019217584B2 (https=)
BR (1) BR112020015991A2 (https=)
CA (1) CA3089211A1 (https=)
IL (1) IL276200B2 (https=)
MX (1) MX2020008294A (https=)
MY (1) MY204220A (https=)
SG (1) SG11202006902QA (https=)
TW (1) TWI889647B (https=)
WO (1) WO2019154867A1 (https=)
ZA (1) ZA202004370B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201805064SA (en) * 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
NZ576284A (en) 2003-01-10 2010-07-30 Ablynx Nv Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン.ヴェー. 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006074947A2 (en) 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2252303A2 (en) 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
DK3412305T3 (da) 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.

Similar Documents

Publication Publication Date Title
JP2024001135A5 (https=)
Mahmoud et al. Treatment of MIS-C in children and adolescents
JP2022537780A5 (https=)
JP2020120689A5 (https=)
Guan et al. Long‐term results of splenectomy in adult chronic immune thrombocytopenia
Hakkarainen et al. Tolfenamic acid is as effective as ergotamine during migraine attacks
KR100912381B1 (ko) 응고 관련 질병을 치료하기 위한 조성물 및 방법
US20110262386A1 (en) Methods of treating inflammation
JP2020002171A5 (https=)
JP2023089191A5 (https=)
JP2021526534A5 (https=)
JP2021510523A5 (https=)
JP2017113019A5 (https=)
JP2023505492A5 (https=)
JP2022505585A5 (https=)
JP2019505527A5 (https=)
CN101107268A (zh) 针对ngf的特异性结合成员
JP2019511911A5 (https=)
JP2019031567A5 (https=)
JP2022538083A5 (https=)
JP2024105229A5 (https=)
KR20120105429A (ko) 염증 치료 방법
JP2022538089A5 (https=)
JP2022523972A5 (https=)
JP2021503891A5 (https=)